Pernix Therapeutics to Present at the 25th Annual ROTH Growth Conference
25th Annual ROTH Conference
THE WOODLANDS, Texas -- March 11, 2013
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that Cooper Collins, President and Chief Executive
Officer, will present at the 25^th Annual ROTH Growth Stock Conference on
Tuesday, March 19, 2013 at 9:30 a.m. PDT. The conference will be held at The
Ritz Carlton in Dana Point, CA.
The presentation will be broadcast live over the Internet and can be accessed
on the Company’s website, www.pernixtx.com, under “Webcasts and Presentation”
on the investor relations section. The audio-recording of the presentation
will be archived on the Company’s website for approximately 30 days following
the conclusion of the presentation.
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company promotes its branded pediatric and gastroenterology products through
its sales force. Pernix markets its generic products through its wholly-owned
subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The
Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures
and packages products for the pharmaceutical industry in a wide range of
dosage-forms. A product candidate utilizing cough-related intellectual
property is in development for the U.S. OTC market. Founded in 1996, the
Company is based in The Woodlands, TX.
Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.
Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, 800-793-2145 ext. 3002
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.